Research Projects (Third party funds)


A Eurropean Infrastructure of Ligand Binding Molecules against the Human Proteome

ProteomeBinders is a European consortium proposing to establish a comprehensive infrastructure resource of binding molecules for detection of the human proteome, together with tools for their use and applications in studying proteome function and organisation.
This 4-year FP6 Research Infrastructures Coordination Action, started in March 2006, is funded with 1.8 M€ and links 25 EU and 2 USA partners, leaders in the area of binders and their applications. The project is coordinated by Dr Mike Taussig (Cambridge). We advocate the organisation of an infrastructure of binders, available at cost and with no restrictions for research use, for which we are applying for funding under FP7.
Currently there is no pan-European platform for the systematic development and quality control for these essential reagents. We aim to provide a set of consistently characterised binders, required to detect all the relevant human proteins in tissues and fluids in health and disease. As the size of the human proteome is at least an order of magnitude greater than the ~ 21.000 protein coding genes known to date, and as for many applications several binders against each target are needed, the scale of our project is potentially immense.
To date, antibodies are the most widely used protein-binders, but novel binder types based on alternative protein scaffolds, nucleic acids, peptides and chemical entities each have significant advantages and will be carefully evaluated. We will coordinate a European resource by integrating existing infrastructures, reviewing technologies and high-throughput production methods, standardising tools and applications, and establishing a database.
Being one of the largest genome-scale projects in Europe, aiming ultimately to produce and collect hundreds of thousands of specific binders, the ProteomeBinders resource will bring huge benefits for basic and applied research, impacting on healthcare, diagnostics, target discovery for drug intervention and therapeutics.



Department of Immunotechnology, Lund University, Sweden
Create Health - Strategic Centre for Clinical Cancer Research

Biosciences Division, Los Alamos National Laboratory, USA

University College, Dublin, Ireland

CNRS-Universités Aix-Marseille I & II, France

Department of Biotechnology, Technical University Braunschweig, Germany
Antibody Factory

Department of Chemical Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Structural and Computational Biology Unit, EMBL, Heidelberg, Germany
ELM: Functional sites in proteins
phosphoELM: S/T/Y phosphorylation sites

SomaLogic Inc., Boulder CO, USA

Department of Biochemistry, University of Kassel, Germany

Proteomics Services, European Bioinformatics Institute, Hinxton, UK
HUPO-PSI: Proteomics Standards Initiative

Division of Functional Genome Analysis, German Cancer Research Center, Heidelberg, Germany

NMI, Tübingen, Germany

VTT Technical Research Centre of Finland, Turku, Finland

In-vitro ligand screening group, Max Planck Institute of Molecular Genetics, Berlin, Germany
Antibody Factory

Genomics & Proteomics Core Facilities, German Cancer Research Center, Heidelberg, Germany

Advanced Molecular Techniques in Genetics, Proteomics, and Medicine, The Rudbeck Laboratory, Uppsala University, Sweden
MolTools - developing tools for the postgenomic era

Center for Human and Clinical Genetics at the Leiden University Medical Center, Leiden, The Netherlands

imaGenes, Berlin, Germany

Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK

Dept. of Molecular and Cellular Interactions, VIB, Vrije Universiteit Brussel, Brussels, Belgium

School of Biotechnology, KTH, Stockholm, Sweden

Department of Biochemistry, University of Zurich, Switzerland

Medical Faculty University of Rijeka, Croatia

Laboratory of Analytical Chemistry and Biopolymer Structure Analysis, University of Konstanz, Germany

EMBL Monoclonal Antibody Core Facility, Monterotondo, Italy

Laboratoire Bordelais de Recherche en Informatique, Bordeaux, France
ProteomeBinders Bioinformatics Wiki

Biologische Chemie, Technische Universitaet Muenchen, Germany

Protein Technology Group,
Babraham Bioscience Technologies, Cambridge, UK
ESF Programme on Integrated Approaches for Functional Genomics
MolTools - developing tools for the postgenomic era

GSF - National Research Center for Environment and Health, Munich, Germany
Partner in Interaction Proteome (EU FP6 IP)

School of Biotechnology, KTH, Stockholm, Sweden
Human Protein Atlas: expression and localisation of proteins in human normal and cancer tissues






Ronald Frank/Jutta Eichler


Babraham Bioscience Technologies Ltd (UK)

Funding agency


PrintSend per emailShare